期刊
NATURE GENETICS
卷 46, 期 6, 页码 601-606出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/ng.2974
关键词
-
资金
- US National Institutes of Health [1P50CA127003-07, 1P50CA168512-01, 5R01DK058185-12]
- Virginia and Daniel K. Ludwig Trust
- GIST Cancer Research Fund
- Life Raft Group
- Cesarini Pan-Mass Challenge for GIST
- Paul's Posse of the Pan-Mass Challenge
- Bernard F. and Alva B. Gimbel Foundation
- Sarcoma Alliance for Research Through Collaboration
- Erica Kaitz LMS Research NOW Fund
Many common human mesenchymal tumors, including gastrointestinal stromal tumor (GIST), rhabdomyosarcoma (RMS) and leiomyosarcoma (LMS), feature myogenic differentiation(1-3). Here we report that intragenic deletion of the dystrophin-encoding and muscular dystrophy-associated DMD gene is a frequent mechanism by which myogenic tumors progress to high-grade, lethal sarcomas. Dystrophin is expressed in the non-neoplastic and benign counterparts of GIST, RMS and LMS tumors, and DMD deletions inactivate larger dystrophin isoforms, including 427-kDa dystrophin, while preserving the expression of an essential 71-kDa isoform. Dystrophin inhibits myogenic sarcoma cell migration, invasion, anchorage independence and invadopodia formation, and dystrophin inactivation was found in 96%, 100% and 62% of metastatic GIST, embryonal RMS and LMS samples, respectively. These findings validate dystrophin as a tumor suppressor and likely anti-metastatic factor, suggesting that therapies in development for muscular dystrophies may also have relevance in the treatment of cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据